Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
Tectonic Therapeutic, Inc. (TECX)
Company Research
Source: GlobeNewswire
TX45 is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF), a serious condition estimated to affect over 600,000 people in the U.S. alone, currently with no approved therapiesPlanned initiation of global, 24-week Phase 2 clinical trial to evaluate TX45 administered subcutaneously in subjects with Group 2 PH due to HFpEF (PH-HFpEF) in the third quarter of 2024, with topline trial results expected in 2026Phase 1a topline trial results of TX45 in healthy volunteers are expected to be released this September, with detailed data to be subsequently presented at a scientific meetingPhase 1b hemodynamic trial evaluating single doses of TX45 in subjects with Group 2 PH-HFpEF continues to enroll as planned, with topline study results expected in mid-2025 WATERTOWN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechno
Show less
Read more
Impact Snapshot
Event Time:
TECX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TECX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TECX alerts
High impacting Tectonic Therapeutic, Inc. news events
Weekly update
A roundup of the hottest topics
TECX
News
- Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Tectonic Therapeutic reports findings from Phase Ia trial of TX45 [Yahoo! Finance]Yahoo! Finance
- Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45GlobeNewswire
- Tectonic Therapeutic (NASDAQ: TECX) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $55.00 price target on the stock.MarketBeat
- Tectonic Therapeutic to Participate in September Investor ConferencesGlobeNewswire
TECX
Sec Filings
- 9/26/24 - Form SC
- 9/26/24 - Form 4
- 9/19/24 - Form 8-K
- TECX's page on the SEC website